Mediwound Ltd (NASDAQ:MDWD) has been assigned a $10.00 price objective by research analysts at Oppenheimer Holdings Inc. in a report released on Monday, May 8th. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer Holdings Inc.’s price objective points to a potential upside of 47.06% from the stock’s previous close.
Separately, Zacks Investment Research downgraded Mediwound from a “hold” rating to a “sell” rating in a report on Tuesday, February 21st. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Mediwound presently has a consensus rating of “Buy” and a consensus price target of $10.75.
Shares of Mediwound (NASDAQ:MDWD) traded up 0.74% during midday trading on Monday, reaching $6.85. 12,187 shares of the company were exchanged. Mediwound has a 52 week low of $4.25 and a 52 week high of $8.58. The firm’s market capitalization is $150.22 million. The firm has a 50-day moving average of $6.41 and a 200 day moving average of $5.81.
Mediwound (NASDAQ:MDWD) last issued its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.03. Mediwound had a negative net margin of 1,776.06% and a negative return on equity of 148.23%. The firm had revenue of $0.54 million during the quarter, compared to the consensus estimate of $0.56 million. During the same quarter last year, the firm posted ($0.17) earnings per share. Mediwound’s revenue was up 112.6% compared to the same quarter last year. On average, equities research analysts expect that Mediwound will post ($0.78) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Mediwound Ltd (MDWD) PT Set at $10.00 by Oppenheimer Holdings Inc.” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/05/19/mediwound-ltd-mdwd-given-a-10-00-price-target-by-oppenheimer-holdings-inc-analysts-updated.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN acquired a new position in Mediwound during the third quarter valued at about $202,000. Citadel Advisors LLC boosted its position in Mediwound by 4.5% in the third quarter. Citadel Advisors LLC now owns 33,622 shares of the biopharmaceutical company’s stock valued at $259,000 after buying an additional 1,456 shares during the last quarter. Renaissance Technologies LLC boosted its position in Mediwound by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 74,300 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 7,900 shares during the last quarter. Baker BROS. Advisors LP acquired a new position in Mediwound during the third quarter valued at about $1,740,000. Finally, Broadfin Capital LLC boosted its position in Mediwound by 19.2% in the fourth quarter. Broadfin Capital LLC now owns 633,102 shares of the biopharmaceutical company’s stock valued at $2,899,000 after buying an additional 102,117 shares during the last quarter. 27.49% of the stock is owned by institutional investors.
Mediwound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for Mediwound Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound Ltd and related companies with MarketBeat.com's FREE daily email newsletter.